StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.63+0.09 (+1.19%)

Close on Nov 18, 2026Market cap $44.12MP/E –Yield –

Xilio Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Xilio Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $64.09M, up 327.3% year over year. For fiscal 2025 it was $43.77M, up 589.9% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$43.77M+589.9%
FY2024Dec 31, 2024$6.34M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$18.69M+131.2%
Q1 FY2026Mar 31, 2026$12.65M+331.7%
Q4 FY2025Dec 31, 2025$13.69M+693.9%
Q3 FY2025Sep 30, 2025$19.07M+742.5%
Q2 FY2025Jun 30, 2025$8.08M+243.0%
Q1 FY2025Mar 31, 2025$2.93M–
Q4 FY2024Dec 31, 2024$1.72M–
Q3 FY2024Sep 30, 2024$2.26M–
Q2 FY2024Jun 30, 2024$2.36M–

More Xilio Therapeutics figures

See a number that looks wrong?